{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:12:11Z","timestamp":1792206731335,"version":"4.4.0"},"reference-count":32,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2023.12170","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T06:31:26Z","timestamp":1692253886000},"source":"Crossref","is-referenced-by-count":6,"title":["Anti\u2011BCMA CAR\u2011T cell immunotherapy for relapsed or refractory multiple myeloma"],"prefix":"10.3892","volume":"26","author":[{"given":"Xiaohui","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, Handan Central Hospital, Handan, Hebei 056001, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Beijing 100037, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, Handan Central Hospital, Handan, Hebei 056001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Handan Central Hospital, Handan, Hebei 056001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Qi","sequence":"additional","affiliation":[{"name":"Good Clinic Practice, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Suo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Handan Central Hospital, Handan, Hebei 056001, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"key20231010100533_b1-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20231010100533_b2-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","article-title":"Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma","volume":"35","author":"van Beurden-Tan","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20231010100533_b3-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"key20231010100533_b4-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12185-020-02829-6","article-title":"Molecular basis of clonal evolution in multiple myeloma","volume":"111","author":"Furukawa","year":"2020","journal-title":"Int J Hematol"},{"issue":"53","key":"key20231010100533_b5-ETM-26-4-12170","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00878-2","article-title":"Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"key20231010100533_b6-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"key20231010100533_b7-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","article-title":"Anti-CD19 CAR T-cell therapy for B-cell non-hodgkin lymphoma","volume":"34","author":"Abramson","year":"2020","journal-title":"Transfus Med Rev"},{"key":"key20231010100533_b8-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: State of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1821","key":"key20231010100533_b9-ETM-26-4-12170","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-Based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"key20231010100533_b10-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-Cell maturation antigen-expressing hematological malignances by Anti-B-Cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"161","key":"key20231010100533_b11-ETM-26-4-12170","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"key20231010100533_b12-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20231010100533_b13-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20231010100533_b14-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"key20231010100533_b15-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"150","DOI":"10.24272\/j.issn.2095-8137.2021.363","article-title":"Engineered T cells and their therapeutic applications in autoimmune diseases","volume":"43","author":"Bao","year":"2022","journal-title":"Zool Res"},{"key":"key20231010100533_b16-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"key20231010100533_b17-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"key":"key20231010100533_b18-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"key20231010100533_b19-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/CCO.0000000000000668","article-title":"CD19-directed CAR T-cell therapy in B-cell NHL","volume":"32","author":"Kersten","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"key20231010100533_b20-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"key20231010100533_b21-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"key20231010100533_b22-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"key20231010100533_b23-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"key20231010100533_b24-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"key":"key20231010100533_b25-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00277-023-05188-4","article-title":"Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients-real world evidence analysis","volume":"102","author":"Stork","year":"2023","journal-title":"Ann Hematol"},{"key":"key20231010100533_b26-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an Anti-B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20231010100533_b27-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"141","key":"key20231010100533_b28-ETM-26-4-12170","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"key20231010100533_b29-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making better chimeric antigen receptors for adoptive T-cell therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20231010100533_b30-ETM-26-4-12170","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa trial using CD19-Targeted Third-Generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"eaaw2127","key":"key20231010100533_b31-ETM-26-4-12170","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2127","article-title":"Driving CAR T cell translation forward","volume":"11","author":"Schultz","year":"2019","journal-title":"Sci Transl Med"},{"issue":"eaav1648","key":"key20231010100533_b32-ETM-26-4-12170","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T07:09:55Z","timestamp":1696921795000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2023.12170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8,17]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2023.12170","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"article-number":"471"}}